ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Carcinoma
Interventions: COMBINATION_PRODUCT: Endocrine therapy|COMBINATION_PRODUCT: Endocrine therapy combined with the local treatment of FES-negative lesions|COMBINATION_PRODUCT: Chemotherapy
Sponsor: Institut Curie
Collaborators: Zionexa